A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Clinical trial NCT05959694 · UNKNOWN
Trial details
- NCT number
- NCT05959694
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-11
- Primary completion
- 2025-12-01
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.